American International Group Inc. Purchases 208 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

American International Group Inc. increased its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,924 shares of the biotechnology company’s stock after purchasing an additional 208 shares during the period. American International Group Inc.’s holdings in Axon Enterprise were worth $5,147,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. EP Wealth Advisors LLC bought a new position in shares of Axon Enterprise in the 4th quarter worth $323,000. Virtu Financial LLC bought a new position in shares of Axon Enterprise in the 4th quarter worth $439,000. Cim LLC purchased a new stake in Axon Enterprise in the 4th quarter valued at $1,409,000. V Square Quantitative Management LLC raised its position in Axon Enterprise by 22.1% in the 4th quarter. V Square Quantitative Management LLC now owns 1,750 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 317 shares during the last quarter. Finally, Comerica Bank raised its position in Axon Enterprise by 1.3% in the 4th quarter. Comerica Bank now owns 143,527 shares of the biotechnology company’s stock valued at $37,077,000 after buying an additional 1,777 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Argus assumed coverage on Axon Enterprise in a research report on Wednesday, March 13th. They issued a “buy” rating and a $380.00 price target for the company. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research report on Wednesday, April 24th. Craig Hallum increased their price target on Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. JPMorgan Chase & Co. increased their price target on Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a research report on Thursday, April 11th. Finally, Barclays increased their price target on Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a research report on Wednesday, May 8th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $335.27.

Axon Enterprise Stock Down 0.7 %

AXON stock opened at $291.15 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91. The company has a market capitalization of $21.97 billion, a price-to-earnings ratio of 85.13 and a beta of 0.91. Axon Enterprise, Inc. has a fifty-two week low of $175.37 and a fifty-two week high of $329.87. The stock has a fifty day moving average of $295.73 and a 200-day moving average of $283.00.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.20. The company had revenue of $460.74 million during the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The firm’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.51 EPS. As a group, equities research analysts predict that Axon Enterprise, Inc. will post 2.35 earnings per share for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the completion of the transaction, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the completion of the transaction, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Julie A. Cullivan sold 478 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $286.04, for a total value of $136,727.12. Following the completion of the transaction, the director now owns 5,546 shares of the company’s stock, valued at approximately $1,586,377.84. The disclosure for this sale can be found here. Insiders sold a total of 89,447 shares of company stock worth $27,684,677 in the last quarter. 6.10% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.